Scinai Immunotherapeutics Holds Shareholder Meeting
Ticker: SCNI · Form: 6-K · Filed: Aug 12, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
Scinai held a shareholder meeting on Aug 12, 2024 with over 3.3B shares eligible to vote.
AI Summary
On August 12, 2024, Scinai Immunotherapeutics Ltd. held an Extraordinary Meeting of Shareholders. The total number of ordinary shares eligible to vote was 3,349,222,240.
Why It Matters
This filing indicates a formal shareholder meeting took place, which is a standard corporate governance event for companies.
Risk Assessment
Risk Level: low — The filing is a routine report of a shareholder meeting and does not contain significant new financial or operational information.
Key Numbers
- 3,349,222,240 — Ordinary Shares (Eligible to vote at the Extraordinary Meeting of Shareholders on August 12, 2024.)
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- August 12, 2024 (date) — Date of Shareholder Meeting
- 3,349,222,240 (dollar_amount) — Number of Ordinary Shares Entitled to Vote
FAQ
What was the purpose of the Extraordinary Meeting of Shareholders held on August 12, 2024?
The filing does not specify the agenda or purpose of the Extraordinary Meeting of Shareholders.
What were the outcomes of the shareholder votes at the meeting?
The filing reports the total number of shares entitled to vote but does not detail the outcomes of any votes.
Did Scinai Immunotherapeutics Ltd. announce any new strategic initiatives or financial updates at the meeting?
This Form 6-K filing only reports the occurrence of the meeting and the number of voting shares; it does not contain details of announcements made.
What is the significance of the company formerly being known as BiondVax Pharmaceuticals Ltd.?
The company changed its name from BiondVax Pharmaceuticals Ltd. to Scinai Immunotherapeutics Ltd. on June 24, 2014.
Where are Scinai Immunotherapeutics Ltd.'s principal executive offices located?
The principal executive offices are located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 17.8 · Accepted 2024-08-12 14:13:36
Filing Documents
- ea0211152-6k_scinai.htm (6-K) — 15KB
- 0001213900-24-067584.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Scinai Immunotherapeutics Ltd August 12, 2024 /s/ Amir Reichman Amir Reichman Chief Executive Officer 2